Triamterene Enhances the Blood Pressure Lowering Effect of Hydrochlorothiazide in Patients with Hypertension

ABSTRACTBACKGROUNDTriamterene, because of its potassium-sparing properties, is frequently used in combination with hydrochlorothiazide (HCTZ) to treat patients with hypertension. By inhibiting the epithelial sodium channel (ENaC) in the cortical collecting duct, triamterene reduces potassium secretion, thus reducing the risk of hypokalemia. Whether triamterene has an independent effect on blood pressure (BP) has not been well studied.OBJECTIVETo determine if triamterene provides an effect to further lower BP in patients treated with HCTZ.DESIGNWe conducted an observational study using electronic medical record data from the Indiana Network for Patient Care. Participants were 17,291 patients with the diagnosis of hypertension between 2004 and 2012.MAIN MEASURESBP was the primary outcome. We compared the BP between patients who were taking HCTZ, with and without triamterene, either alone or in combination with other antihypertensive medications, by using a propensity score analysis. For each medication combination, we estimated the propensity score (i.e., probability) of a patient receiving triamterene using a logistic regression model. Patients with similar propensity scores were stratified into subclasses and BP was compared between those taking triamterene or not within each subclass; the effect of triamterene was then assessed by combining BP differences estimated from all subclasses.KEY RESULTSThe mean systolic BP in the triamterene + HCTZ group was 3.8 mmHg lower than in the HCTZ only group (p < 0.0001); systolic BP was similarly lower for patients taking triamterene with other medication combinations. Systolic BP reduction was consistently observed for different medication combinations. The range of systolic BP reduction was between 1 and 4 mm Hg, depending on the concurrently used medications.CONCLUSIONSIn the present study, triamterene was found to enhance the effect of HCTZ to lower BP. In addition to its potassium-sparing action, triamterene’s ability to lower BP should also be considered.

[1]  J. Runyan.  Influence of thiazide diuretics on carbohydrate metabolism in patients with mild diabetes. , 1962, The New England journal of medicine.

[2]  Y. Morin,et al.  TRIAMTERENE: CLINICAL STUDIES IN ARTERIAL HYPERTENSION. , 1965, American heart journal.

[3]  B. Gage,et al.  Accuracy of ICD-9-CM Codes for Identifying Cardiovascular and Stroke Risk Factors , 2005, Medical care.

[4]  E. Eleuteri.  [Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[5]  John S. Scott,et al.  Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. , 2000, Journal of the American College of Cardiology.

[6]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[7]  Jackson T. Wright,et al.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). , 2014, JAMA.

[8]  Xiao-Hua Zhou,et al.  The use of propensity scores in pharmacoepidemiologic research , 2000, Pharmacoepidemiology and drug safety.

[9]  J. Pratt,et al.  Central role for ENaC in development of hypertension. , 2005, Journal of the American Society of Nephrology : JASN.

[10]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[11]  P. Austin.  An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies , 2011, Multivariate behavioral research.

[12]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[13]  G. Bray,et al.  Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet , 2001 .

[14]  L. Schild,et al.  Epithelial Sodium Channel: Mendelian Versus Essential Hypertension , 2008, Hypertension.

[15]  D. Calhoun,et al.  Aldosterone receptor antagonists: current perspectives and therapies , 2013, Vascular health and risk management.

[16]  Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group. , 1985, Journal of hypertension.

[17]  B. Olofsson,et al.  Atenolol in Secondary Prevention after Stroke , 1995 .

[18]  J. Rowe,et al.  Effect of experimental potassium deficiency on glucose and insulin metabolism. , 1980, Metabolism: clinical and experimental.

[19]  G. Mancia,et al.  Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of the European Lacidipine Study on Atherosclerosis (ELSA), a Randomized, Double-Blind, Long-Term Trial , 2002, Circulation.

[20]  M. Moser,et al.  Fifty years of thiazide diuretic therapy for hypertension. , 2009, Archives of internal medicine.

[21]  B Neal,et al.  Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials , 2000, The Lancet.

[22]  Lonnie Blevins,et al.  The Indiana network for patient care: a working local health information infrastructure. An example of a working infrastructure collaboration that links data from five health systems and hundreds of millions of entries. , 2005, Health affairs.

[23]  Anneliese M Gerland,et al.  Physicians' experiences using commercial e-prescribing systems. , 2007, Health affairs.

[24]  K. Murray,et al.  Treatment of elderly hypertensive patients with epithelial sodium channel inhibitors combined with a thiazide diuretic reduces coronary mortality and sudden cardiac death. , 2008, Journal of the American Society of Hypertension : JASH.

[25]  D. Thurber,et al.  Potassium‐Sparing Effects of Triamterene in the Treatment of Hypertension , 1966, Circulation.

[26]  M. Moser,et al.  Use of diuretics in patients with hypertension. , 2009, The New England journal of medicine.

[27]  Konrad Jamrozik.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002 .

[28]  W. Ambrosius,et al.  Improvement in Blood Pressure With Inhibition of the Epithelial Sodium Channel in Blacks With Hypertension , 2005, Hypertension.

[29]  A. Hofman,et al.  Diuretics, -Blockers, and the Risk for Sudden Cardiac Death in Hypertensive Patients , 1995, Annals of Internal Medicine.

[30]  J. Laragh,et al.  Triamterene-induced changes in aldosterone and renin values in essential hypertension. Evidence of a role for aldosterone in preventing blood pressure reduction. , 1976, Archives of internal medicine.

[31]  Donald Rubin,et al.  Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.

[32]  E. Freis,et al.  Potassium restoration in hypertensive patients made hypokalemic by hydrochlorothiazide. , 1990, Archives of internal medicine.

[33]  W. I. Cranston,et al.  Effect of triamterene on elevated arterial pressure. , 1965, American heart journal.

[34]  et al.,et al.  The Regenstrief Medical Record System: a quarter century experience , 1999, Int. J. Medical Informatics.